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Association rule mining does not restrict to market basket application but it is also employed in 
many applications such as health, industrial, network domain and etc. In this paper, an association 
mining algorithm is applied to the health management domain. It helps in the decision making by 
producing the rules for the early detection of the disease. By checking the personal details and 
symptoms of the patient, association rule mining will help in prediction and diagnosing the disease 
at an early stage. The dataset used in this experiment is the Huntington Disease (HD) dataset, 
which is one of the rare diseases. The dataset needs to be stored in the memory for the computation 
and generation of rules. Storing the items in the memory will take 4 bytes if the array data structure 
is used. Furthermore, if the dataset is very large, storing each and every detail in the memory 
becomes speculative. It is also not cost-effective and consumes a lot of resources. One of the 
solutions is to present the itemset in such a way that the memory consumed is concise. The items 
are represented using the set representation that takes less time and memory as compared to the 
traditional methods. The dataset is mine using the Apriori Algorithm which produces only those 
itemsets which are more frequent or have a high probability of occurrence. The algorithm gives a 
prior knowledge of the frequent itemsets. Then, the rules will be generated from these frequent 
itemsets. The memory and time consumption using the set representation is compared with the 
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We live in era where mental health plays a significant role than the physical health. Mental health refers to the 
emotional, behavioural, psychological and social well- being of an individual. In the olden days, a person is considered 
sick whenever he can’t physically commit to his duties [1]. Since not much importance was given to it, most of the 
people were not aware about mental illness. There are new research from BCBSA (Blue cross blue shield association) 
which reported that many of the millennial are less healthy especially those belonging to the age group of 34 to 36. 
Survey shows that in the top 10 health conditions, the number of millennial are more as compared to the others. With 
regard to the national population, they are affected more by the behavioural or mental health than physical, where 
depression and hyperactivity are the leading causes. Depression, behavioural, cognitive conditions are some of the 
symptoms contributing to Huntington disease [2]. 
Huntington disease is a rare disease which is neuro-degenerate disorder that occurs in the central nervous system. 
This disease is characterized by the behavioural disturbance, dementia and unwanted choreatic movement of a person. 
It is most frequently seen in the Caucasian population in the age group is 30-50 years. Some of the symptoms are 
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dominantly prevalent for a person aged 20 years with the 5-10 per 100000 populations of the Caucasian people. Some 
of them have the inability of learning and behavioural difficulties at school. Huntington disease’s principle sign is chorea. 
This disease spreads first to the muscles and then to the psychomotor processes which have been severely retarded. 
Patients will also experience the psychiatric symptoms [1, 2]. 
1-1- History 
The Huntington’s case was first reported by Waters in the late 1842 but it was until 1847, when the description of 
this disease was given by George Huntington which later become known as Huntington’s chorea. It is a neuro-
degenerative disorder which is passed from generation to generation from families ranging from dementia to psychiatric 
disturbances [1]. It was until the ninetieth – eighties when the symptoms were more extensive with non-motor signs 
where it is then known as the Huntington’s disease. In 1983, it was discovered that there was a link to the chromosome 
4 and in 1993 a gene for this disease was found [3]. This is the first time where the diagnosis has been made. The disease 
contains repeat of the CAG (Cytosine (C), Adenine and Guanine). CAG is a trinucleotide that is the building block for 
DNA. It is also the codon for amino acid [1-3]. 
1-2- Symptoms 
The symptoms of the Huntington’s disease are disturbances relating to motor, psychiatric and cognitive. Other 
prevalent symptoms include loss of sleep and weight along with autonomic nervous system dysfunction. The disease is 
mostly common for the population of the age gap of 17-20 years. Death is mostly because of pneumonia which is then 
followed by suicide. Some of them are as follows:- 
Motor Signs 
The features of the motor changes are unwanted and involuntary movements which occurs in the finger, toes and 
other facial extremities. It also affects the daily life of a person and these are visible to the eye of bystanders. The person 
is nervous. His/her talking and walking is unstable which makes the person looks like he/she is drunk. Swallowing is 
another problem which causes choking in some patients. Patients also experiences dystonia which is characterized by 
slower movements, abnormal posture of the limbs or trunk. Hyperkinesia and hypokinaemia is also seen in patients 
which results in abnormal walking, standing. This causes ataxic gait which may lead to frequent fall [1, 3]. 
Behavioural and Psychiatric Symptoms 
These symptoms are common in the early stage of the disease. They impact the daily life a patient and has a highly 
negative impact on the family life. The signs are anxiety, low self-esteem which leads to depression. Suicide is prevalent 
at the onset of the disease. Obsession can occurs which may lead to frustration in patients. Psychosis may appear in the 
later stage [3, 4]. 
Dementia 
Cognitive decline is also one of the sign of the Huntington disease. Patients cannot separate activities that need 
attention and ones that needs to be ignored. They will be not able to organize their tasks in their day to day life. They 
are neither able to make adjustments nor have the peace of mind. These misjudgements may lead to complicated situation 
where the patients is not able to make decisions in that particular environment in which he is expected to do so. Memory 
and language becomes severely impaired [5]. 
Weight Loss 
Huntington disease also causes weight loss. It is found that the repeated sequence of CAG chain is linked with the 
weight loss [6]. With the course of time, this illness becomes cachectic. It has also been found that the patient who 
imbibed supplements, drugs such as neuroleptics, anti-depressants shows an astonishing pattern. It has been seen that 
the patients who are at the hypokinetic stage are inclined to display more weight loss. Weight loss often, give into 
weakening which results in risk of evolving co- morbidity. This will facilitate the decline in the quality of the patient’s 
life [7]. 
Sleep Complications 
It has been found that the 90% of the people have sleep problems which have been diagnosed with HD. It also been 
reported that 48-80% patients experience nocturnal awakenings in the night. During the nights, the patients experienced 
more activity such as acceleration movements than the other normal people [1]. 
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2- How the Disease Developed? 
The disease starts with one parent who has Huntington disease. Accordingly, Huntington can be categorized into 
three parts: At risk, pre-clinical stage and clinical stage. The first stage is when the patient is diagnosed to carry the 
repeated CAG chain on chromosome 4. The stage ends when the patient is confirmed to carry the chain and then the 
other stages will start. The clinical stage is shown in the Table 1. During stress whether it is psychological or physical, 
the signs will start to manifest. The signs will deteriorate when the person becomes normal. In the past years, the first 
signs are motor signs. However, depending on the type of family and the doctor’s experience, the diagnosis was 
suggested. Over the last 20 years, other signs have also been taken in consideration such as psychiatric and cognitive 
changes in patients. Patients experience burn out in their work space or depression [1].  
Table 1. The stages in Huntington’s disease. 
a. Preclinical Stages  
1. At risk Stage 
Uncertainty of the disease 
Concerned of what lies ahead 
2. Carrier of the gene, early onset stage 
Certainty of the carrier of the gene 
Care for the family which is affected 
3. Transformation phase 
Changes noticed in behaviour 
Changes observed about the cognition 
Changes recognized in motor activity 
b. Clinical Stages  
4. Clinical Stage 1 
Symptoms include neurological, psychiatric or cognitive 
Chorea is more prevalent 
Death is rare except suicide 
5. Clinical Stage 2 
Physical dependence is prominent 
Motor disturbances is observed 
Death occurs by suicide or euthanasia. 
6. Clinical Stages 3 
Motor disturbances is more severe. 
Nearly complete physical dependence is needed 
The patient needs complete care 
Death 
3- Treatment 
For clinical practice, antipsychotic drugs are used but their use is limited by complications such as Parkinson disease, 
difficulties in swallowing, impaired balance [8]. 
3-1- Treatment for Depression 
Depression is the most frequent symptoms for the onset in Huntington disease [9]. The metabolic activity is lower 
in the basal ganglia is evident in the depressed patients in HD [10]. Antidepressants used for HD such as clozapine have 
been used for treatment of psychotic depression [11]. There are other positive results found for fluoxetine [12], 
amitryptiline [13], mirtazapine [14], isocarboxazid [15], phenelzine [15], amoxapine [16]. 
3-2- Treatment for Psychotic Symptoms 
Psychotic is common in HD patients [17, 18]. Risperidone shows some improvement for the treatment of the disease. 
3-3- Behavioural Disorder 
Lack of control, aggression, emotional dyscontrol and irritability are some of the symptoms for the behavioural 
disorder. These behaviours cause disturbances to the patient’s family. This will also increase the crime cases especially 
for the male patients. Haloperidol was used to treat patient with irritability, depression and emotional outbursts. 
Olanzapine had showed improvement in treatment of anxiety, irritability and obsessions. 
3-4- Dementia 
Dementia is more prevalent in the clinical stage. Unsaturated fatty acids [19], minocycline [20] provide benefits in 
trials. There is no treatment of the dementia for the level 1 stage. 
3-5- Other Psychotic Symptoms 
Other symptoms such as compulsive or obsessive show deterioration on the neuropsychological tests. Olanzapine 
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has also been used for treatment of obsession in HD [21, 22]. A case was reported that anxiety was treated using 
diazepam, amitryptiline [23]. For hypomania in HD patients, propranolol is used [24]. 
4- Dataset 
4-1- Dataset: Transcription Profiling by Array of Human Lymphocytes from Moderate Stage Huntington’s disease 
Patients  
In the Huntington’s disease (HD) dataset, the transcriptomic test was explored and the mRNA in peripheral blood 
cells were measured. The performance is analysed and the gene immediately early response 3 (IER3) shows a 
predominantly increase in HD samples of 32% compared to controls. This dataset is widely accessible from the website 
link: http://biogps.org/#goto=genereport&id=1017&show_dataset=E-GEOD-8762. The overall design of the experiment 
consists of samples from 12 (8 females and 4 males) HD patients at moderate stage and 10 (5 females and 5 males) 
matched controls samples. 
In this paper, the dataset is being tested using the set and array representation for association rule mining. When 
analysing the clinical stage 1, the patients cannot be tested positive for HD. However, there are instances where the 
patients showing symptoms at the clinical stage 1 are confirmed to have HD. Manually, the physician can sometimes 
miss out the symptoms and prescribe wrong medications for the patients. The patient is very local and put full faith on 
the doctor. They will never cross question or question the doctor regarding the mediation. This is very common where 
the patients consume wrong medications which deteriorate the health of the patients. These are those cases that leads to 
the death of the patient. The total number of individuals taken for the experiment is 22. The personal details of the 
individuals are taken and their counts for CAG repeats are being analysed. The main essential sign of HD is the repeat 
of the CAG gene and so by checking the CAG gene repeat can help us to find out whether the patient is diagnosed with 
HD or not. 
4-2- Dataset: Transcription Profiling of Human Blood from Huntington’s disease Patients 
In the second dataset, the transcription profile of human blood is analysed and studied. In this dataset, there are 31 
samples of human blood which contains the affymetrix U133A expression levels for 17 Huntington’s disease patients 
where 5 are presymptomatic and 12 symptomatic versus 14 are healthy controls. The dataset is available in the website 
http://biogps.org/dataset/E-GEOD-1751/transcription-profiling-of-human-blood-from-huntin/. This dataset contains the 
changes in blood mRNAs of human where there is a clear distinction between HD patient and the controls. These 
changes that occurs inside the mRNA expressions that clearly distinguish HD patients from the controls. These 
alterations in mRNA expression associate with how the disease progresses in the experiment. All these alternations may 
predict the onset of the disease at the clinical trial.  
Although not much research has been in this field, the disease is very life threatening. HD is very rare and finding 
the samples for this disease is difficult. However, analysing this dataset by using the association rule mining algorithms 
will help in decision making. Manually, diagnosing hundreds of patients is difficult and sometimes, the doctors may 
miss out. Using association rule mining, finding the patients which are diagnosed with HD is much easier and faster as 
compared to manual work. Moreover, there may be some errors especially manual error. Hence, association rule mining 
is more efficient and effective. 
Furthermore, if the datasets is very large and storing such large datasets will consume space. In the medical domain, 
the population is very large and keeps on growing. Storing the patient details and the symptoms is not feasible and cost 
effective.  
There will be many attributes for storing the patient’s both personal and medical details. In the memory, each element 
needs to be stored using a data structure. Using the array representation, each element consumes 4 bytes. In this way, if 
there are 10 attributes for dataset with 1000 individuals, the memory that needs to be reserve will be 10×4 (4 bytes 
each)= 40×1000 (1000 individuals) that will be 40,000 bytes ~ 40 kb. However, using set representation, each data will 
consume only 1 bit. The memory consumption will be 10×4=40 bits (4 bytes). For 1000 individuals, the memory 
consumption will be 40×1000=40000 bits ~ 5000 bytes or 5 kb. 
5- Association Rule Mining Algorithm 
Association rule mining mines the dataset for candidate generation and rule production. One of the most popular 
association rule mining algorithms is Apriori Algorithm. Apriori algorithm scans the dataset and finds the itemsets that 
are more frequent. The frequent itemsets are those itemsets that are most frequently occurring in the entire dataset called 
Large itemsets, 𝐿𝑘. The large itemsets 𝐿𝑘 whose support count is more than the threshold is considered as candidate 
itemsets, 𝐶𝑘 and those itemsets whose support count is less than the threshold is pruned. These candidate itemsets, 𝐶𝑘, 
are self joined to find the next candidate itemsets 𝐶𝑘+1 This process is continued until no other large itemsets are found 
[25].  
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Rules from these itemsets are generated depending on the confidence value. The confidence metrics validates the 
rule. A rule A→B implies that whenever itemset A occurs the itemset B also occurs. The rule is generated for those 
candidate itemsets whose confidence value is more than the threshold value. In the medical domain, association rule is 
used for diagnosing a disease. If the person shows some few symptoms occurring at a particular time then from analysing 
the symptoms, we can conclude that the person is suffering from a certain disease [29, 30].  
6- Set Representation  
The itemsets in the dataset can be represented using two data structures, set representation and the array 
representation [26-28]. In the array representation, each element consumes 4 bytes. An example is taken from the dataset 
for representing the itemset using array. Suppose the itemset I={2, 12, 13, 24, 31}, the representation using array and 
set representation is shown in Figure 1. 
Array Representation 
0 1 2 3 4 ….. 12 13 …… ….. ….. …… 24 …… ….. …… 31 
2 12 13 24 31 …… UD UD …… ….. ….. …… UD …… ….. ….. UD 
 
Set Representation 
0 1 2 ……. …… ….. 12 13 …… ….. ….. …… 24. …… ….. …… 31 
0 0 1 ……. …… ….. 1 1 …… ….. ….. …… 1 …… ….. …… 1 
 
Figure 1. Array and Set Representation of the itemsets I = {2, 12, 13, 24, 31}. 
Using set representation, the union operation for the itemset I = {2, 12, 13, 24, 31} and J = {3, 12, 13, 23, 30} is 
shown in Figure 2. 
I = {2, 12, 13, 24, 31} 
0 1 2 ……. …… ….. 12 13 …… ….. ….. …… 24. …… ….. …… 31 
0 0 1 ……. …… ….. 1 1 …… ….. ….. …… 1 …… ….. …… 1 
 
J = {3, 12, 13, 23, 30} 
0 1 2 3 4 ….. 12 13 …… ….. ….. …… 23 …… ….. 30 31 
0 0 0 1 0 …… 0 1 …… ….. ….. …… 1 …… ….. 1 0 
 
I U J = {2, 3, 12, 13, 24, 30, 31} 
0 1 2 3 4 ….. 12 13 …… ….. ….. 23 24 …… ….. 30 31 
0 0 1 1 0 …… 1 1 …… ….. ….. 1 1 …… ….. 1 1 
 
Figure 2. Union operation of the itemsets I = {2, 12, 13, 24, 31} and J = {3, 12, 13, 23, 30}. 
The intersection operation for the itemset I={2, 12, 13, 24, 31} and J ={3, 12, 13, 23, 30}is shown in Figure 3. 
 
I = {2, 12, 13, 24, 31} 
0 1 2 ……. …… ….. 12 13 …… ….. ….. …… 24. …… ….. …… 31 
0 0 1 ……. …… ….. 1 1 …… ….. ….. …… 1 …… ….. …… 1 
 
J ={3, 12, 13, 23, 30} 
0 1 2 3 4 ….. 12 13 …… ….. ….. …… 23 …… ….. 30 31 
0 0 0 1 0 …… 1 1 …… ….. ….. …… 1 …… ….. 1 0 
 
I ∩ J 
0 1 2 3 4 ….. 12 13 …… ….. ….. 23 24 …… ….. 30 31 
0 0 0 0 0 …… 1 1 …… ….. ….. 0 0 …… ….. 0 0 
 
Figure 3. Intersection operation of the itemsets I = {2, 12, 13, 24, 31} and J = {3, 12, 13, 23, 30}. 
The set difference operation for the itemsets I ={2, 12, 13, 24, 31} and J ={3, 13, 23, 30} is shown in Figure 4. 
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I ={2, 12, 13, 24, 31} 
0 1 2 ……. …… ….. 12 13 …… ….. ….. …… 24. …… ….. …… 31 
0 0 1 ……. …… ….. 1 1 …… ….. ….. …… 1 …… ….. …… 1 
 
J = {3, 13, 23, 30} 
0 1 2 3 4 ….. 12 13 …… ….. ….. …… 23 …… ….. 30 31 
0 0 0 1 0 …… 0 1 …… ….. ….. …… 1 …… ….. 1 0 
 
I – J={2, 12, 24, 31} 
0 1 2 3 4 ….. 12 13 …… ….. ….. 23 24 …… ….. 30 31 
0 0 1 0 0 …… 1 0 …… ….. ….. 0 1 …… ….. 0 1 
 
Figure 4. Set difference operation of the itemsets I = {2, 12, 13, 24, 31} and J = {3, 12, 13, 23, 30}. 
7- Research Methodology 
The research methodology can be explained with the help of the flowchart given in Figure 5. 
 
Figure 5. Flowchart of the methodology. 
8- Results and Discussion 
The set and array representation are tested on the Huntington’s first dataset. The dataset is mine using the Apriori 
algorithm. The performance of the set and array representation is tested with different ranging values of support and 
confidence. The performance of these representations is compared in terms of time and memory consumption. In the 
Table 2, with confidence= 1% and support value of 1, 2.5, and 5% the time and memory consumption of each 
representation is explored. 
Table 2. Array and set representation of itemsets for Apriori Algorithm with confidence value=1% and Support =1, 2.5, and 5%. 
Confidence =1% 
Array representation of itemsets 
for Apriori Algorithm 
Set representation of itemsets for 
Apriori Algorithm 







t 1% 564.544 32048 282.122 15000 
2.5% 232.938 32005 220.186 14924 
5% 222.301 31960 187.448 14916 
The confidence value is changed to 2.5% and support values = 1, 2.5, and 5% and the performance of the algorithm 
is shown in Table 3. Again, in the Table 4, the confidence value is changed to 5% showing the performance of the 
itemsets representation. 
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Table 3. Array and set representation of itemsets for Apriori Algorithm with confidence value=2.5% and Support =1, 2.5, and 5%. 
Confidence =1% 
Array representation of itemsets for 
Apriori Algorithm 
Set representation of itemsets for 
Apriori Algorithm 







t 1% 551.864 32000 245.155 14896 
2.5% 226.938 31956 203.306 14884 
5% 198.301 31940 167.908 14864 
Table 4. Array and set representation of itemsets for Apriori Algorithm with confidence value=5% and Support =1, 2.5, and 5%. 
Confidence =5% 
Array representation of itemsets for 
Apriori Algorithm 
Set representation of itemsets for 
Apriori Algorithm 







t 1% 527.68 31980 215.439 14816 
2.5% 224.357 31956 195.626 14804 
5% 189.921 31952 162.051 13989 
The graphs are created to show the comparison between array and set representation in Figure 6 to 8.   
    
Figure 6. Time and memory consumption of Apriori Algorithm using set and array representation with confidence= 1%. 
    















Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 1%
Array representation of itemsets for Apriori Algorithm



















Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence 
Array representation of itemsets for Apriori Algorithm















Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 2.5%
Array representation of itemsets for Apriori Algorithm



















Memory consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 2.5%
Array representation of itemsets for Apriori Algorithm
Set representation of itemsets for Apriori Algorithm
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Figure 8. Time and memory consumption of Apriori Algorithm using set and array representation with confidence= 5%. 
From the Tables 2 to 4 and Figures 6 to 8, it is seen that the set representation for Apriori Algorithm performs better 
in both time and memory consumption. It also observed that with varying the value of support and confidence, the time 
and memory consumption also changes. 
In the Huntington’s second dataset, the itemset representation is represented using array and set representation. The 
Apriori Algorithm is then used to mine the dataset. The dataset is mine using varying values of support and confidence. 
The performance is tested and measured in terms of memory and time consumption. The result of the time and memory 
consumption is given in the Tables 5 and 7.  
Table 5. The representation of itemset using Array and Set representation for Apriori Algorithm with confidence value=1% 
and Support =1, 2.5, and 5% 
Confidence =1% 
Array representation of itemsets 
for Apriori Algorithm 
Set representation of itemsets for 
Apriori Algorithm 







t 1% 1962.16 32076 611.168 14924 
2.5% 782.699 32056 598.890 14900 
5% 732.16 32024 491.151 14864 
Table 6. The representation of itemset using Array and Set representation for Apriori Algorithm with confidence 
value=2.5% and Support =1, 2.5, and 5%. 
Confidence =2.5% 
Array representation of itemsets 
for Apriori Algorithm 
Set representation of itemsets for 
Apriori Algorithm 







t 1% 1911.61 32041 594.076 14900 
2.5% 744.775 32024 499.613 14888 
5% 730.15 32004 486.151 14876 
Table 7. The representation of itemset using Array and Set representation for Apriori Algorithm with confidence value=5 
% and Support =1, 2.5, and 5% 
Confidence =5% 
Array representation of itemsets 
for Apriori Algorithm 
Set representation of itemsets for 
Apriori Algorithm 







t 1% 778.307 32036 574.432 14892 
2.5% 747.054 31992 496.996 14872 
5% 714.981 31940 476.949 14840 















Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 5%
Array representation of itemsets for Apriori Algorithm



















Time consumption representation of itemsets for Apriori 
Algorithm using array and set representation with 
confidence = 5%
Array representation of itemsets for Apriori Algorithm
Set representation of itemsets for Apriori Algorithm
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Figure 9. Time and memory consumption of Apriori Algorithm using set and array representation with confidence= 1%. 
   
Figure 10. Time and memory consumption of Apriori Algorithm using set and array representation with confidence= 2.5%. 
   














Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 1%
Array representation of itemsets for Apriori Algorithm



















Memory consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 1%
Array representation of itemsets for Apriori Algorithm














Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 2.5%
Array representation of itemsets for Apriori Algorithm



















Memory consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 2.5%
Array representation of itemsets for Apriori Algorithm


















Time consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 5%
Array representation of itemsets for Apriori Algorithm



















Memory consumption representation of itemsets for 
Apriori Algorithm using array and set representation 
with confidence = 5%
Array representation of itemsets for Apriori Algorithm
Set representation of itemsets for Apriori Algorithm
Emerging Science Journal | Vol. 5, No. 3 
Page | 389 
From the Tables 5 to 7 and Figures 9 to 11 it is observed that array representation consumes more time and memory 
as compared to set representation. In the set representation, it is seen that the memory consumption is almost half of 
what array representation takes. Similarly, the time consumption is also less than that of the array representation. It is 
also evident that with increase in the value of confidence and support value, the memory and time consumption for both 
the itemset representation also decreases.  
9- Rules Generation 
The dataset is mine using the Agarwal’s Algorithm. With the varying values of confidence and support value, the 
rules generated show that there are cases where some common patient’s symptoms can lead to Huntington’s disease. 
However, most of the cases show that the patients having repeated CAG chain are prone to have Huntington’s disease. 
The personal details of the patients do not signify that the patient will have the disease. According to the dataset, the 
crucial symptom is the repeated CAG chain signals that the patient has Huntington’s disease. Huntington’s symptoms 
are most mental disease and usually not easily detectable at an early stage. These symptoms are mostly invisible and not 
physical that can be easily spotted by the doctor. The doctor needs time to monitor and observe the behaviour of the 
patient. By using the rule generation algorithm, diagnosing the disease can be done at an early stage.  
10- Conclusion 
Diagnosing the disease at an early stage helps in the process of the treatment of the disease. In the early days, the 
doctor diagnose the disease depending on the symptoms of the patient. Since the Huntington’s disease is very rare 
disease and mostly relating to the mental illness, it is usually not easily detectable. Moreover, diagnosing the disease 
manually will take time if the size of the dataset is large. There is also a probability that manual error can occur during 
the diagnosing process where the doctor may miss out on some crucial symptoms. Furthermore, if the dataset is very 
large it is not feasible for the doctor to manually check each and every patient. The association rule mining algorithm 
mines the dataset to help in the process of decision making providing better accuracy. Using association rule mining 
algorithm such as Agarwal’s Algorithm, the time for diagnosing the disease is also reduced. The computation process 
using the set representation saves time since the computation uses bitwise operation. Most importantly, patient’s life is 
saved where the disease can be diagnose at an earlier stage. The itemsets represented using set representation consumes 
only 1 bit whereas array representation takes about 4 bytes. This saves the memory consumption for storing and 
computation. This also saves the cost and resource for diagnosis and detection of disease especially when the dataset is 
very large. Hence, for an early detection of the disease and better accuracy of disease detection, set representation 
performs better in terms of time and memory consumption as compared to the array representation for mining the dataset.  
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